search
Back to results

Craniomaxillofacial and Upper Extremity Allotransplantation

Primary Purpose

Face Injuries, Hand Injuries, Craniofacial Injuries

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Sponsored by
NYU Langone Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Face Injuries focused on measuring Transplants, Transplantation, Craniomaxillofacial Transplantation, Upper Extremity Transplantation, Vascularized Composite Allotransplantation (VCA)

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed and dated all required Institutional Review Board (IRB) approved consent forms.
  • Male or female recipient between the ages of 18-64 years. Recipients do not need to be of the same sex as the donor.
  • Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage.
  • Missing part of one or both hands and forearms.
  • Must be HIV negative at the time of transplant.
  • Crossmatch is negative at the time of transplant.
  • Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction.
  • Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in upper extremity reconstruction.
  • Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery.
  • The subject is able to complete pre-transplant examination and screening procedures.
  • Patient has been approved by Patient Selection Committee for placement on the recipient waiting list.
  • The subject is willing to continue immunosuppression regimen as directed by treating physician.
  • Subject is willing and able to return to follow-up visits as described in treatment plan.
  • Subjects must have autogenous tissue options available for reconstruction in event of graft failure.
  • Normal glomerular filtration rate (GFR) >60.
  • Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant.

Exclusion Criteria:

  • Uncontrolled infection or severe concomitant diseases which would exclude the recipient from transplantation
  • Serious co-morbidities
  • Positive serology for HIV; Hepatitis B Antigen
  • Active malignancy within 5 years with the exclusion of non-melanoma
  • Substance abuse disorders not currently under control (as determined by the Michigan Alcohol Screening Test - see Appendix N.1: Subjects with a score of 3 or more will be excluded)
  • Body Dysmorphic disorder (see Appendix N.2 for screening tool). Less severe psychiatric conditions are addressed on a case by case basis
  • Active Severe Psychiatric Illness
  • Cognitive limitations affecting the patient's ability to provide informed consent
  • Recent history of medical non-adherence
  • Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other.
  • Recent history of medical non-adherence.
  • Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study
  • Currently active smoker within 1 year
  • Subjects with any cognitive deficits related to a traumatic brain injury (TBI) and or any organic neurological disorders
  • Any other psychological status that would hinder the success or safety of the transplantation.
  • Level of amputation proximal to mid-humerus: some presence of proximal muscles is required to motor a functioning hand.
  • Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post-transplant results
  • History of amputation of less than six months: subject must be allowed to attempt prosthetic use prior to hand transplantation. This can be waived in cases where the recipient requires amputation/revision of the transplant site at the time of transplantation. However, if at all possible, it is highly encouraged that the patient has ruled out prosthetics as an alternative to transplantation.
  • Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation
  • Pregnancy

Sites / Locations

  • NYU Langone HealthRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment group

Arm Description

There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.

Outcomes

Primary Outcome Measures

Change in function of the transplanted facial segment
This will be measured using electromyogram (EMG)
Change in function of the transplanted facial segment
This will be measured using nerve conduction studies (NCS)
Change in function of the transplanted facial segment
This will be measured using computerized tomography angiogram (CTA)
Change in function of the transplanted facial segment
This will be measured using magnetic resonance imaging (MRI)
Change in function of the transplanted facial segment
This will be measured using vision exams
Change in function of the upper extremity transplant
This will be measured using pathology samples to check for rejection
Change in function of the upper extremity transplant
This will be measured using electromyogram (EMG)
Change in function of the upper extremity transplant
This will be measured using nerve conduction studies (NCS)
Change in function of the upper extremity transplant
This will be measured using computerized tomography angiogram (CTA)
Change in function of the upper extremity transplant
This will be measured using magnetic resonance imaging (MRI)
Change in appearance of the transplanted facial segment
This will be measured using photography
Change in appearance of the upper extremity transplant
This will be measured using photography

Secondary Outcome Measures

Full Information

First Posted
August 6, 2019
Last Updated
May 3, 2023
Sponsor
NYU Langone Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04057638
Brief Title
Craniomaxillofacial and Upper Extremity Allotransplantation
Official Title
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 17, 2019 (Actual)
Primary Completion Date
January 1, 2026 (Anticipated)
Study Completion Date
January 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NYU Langone Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.
Detailed Description
The purpose of this study is to see if an investigational surgery that transfers tissue from a non-living donor to a living individual will help restore greater function, appearance, and sensation to the face and upper extremity areas of individuals who have suffered injury to those areas. Upper extremity constitutes the part of the body including arm, forearm and hand. This procedure is called combined craniomaxillofacial and upper extremity allotransplantation or "combined face and upper extremity transplant". This study will also collect data on how patients do during and after having a combined face and upper extremity transplant from a nonliving donor. Recovery and outcomes will be observed through clinical exams, x-rays, blood and tissue tests, and other associated evaluations at all follow up visits. Participants are invited to take part in this research study who have suffered severe injury to the face and upper extremity and previous surgeries to repair the injury have not restored function, appearance, and sensation. Participants must have attempted a trial of prosthetics (artificial upper extremity), if at all possible.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Face Injuries, Hand Injuries, Craniofacial Injuries, Upper Extremity Injuries, Facial Injuries, Facial Deformity
Keywords
Transplants, Transplantation, Craniomaxillofacial Transplantation, Upper Extremity Transplantation, Vascularized Composite Allotransplantation (VCA)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is a prospective longitudinal observational analysis of functional and aesthetic outcomes after treatment of severe facial defects and upper extremity injuries with microvascular composite tissue allotransplantation. There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Experimental
Arm Description
There will only be the treatment group in this study, which undergoes microvascular VCA transplantation. There will be no randomization, placebo or control groups.
Intervention Type
Procedure
Intervention Name(s)
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Intervention Description
Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Primary Outcome Measure Information:
Title
Change in function of the transplanted facial segment
Description
This will be measured using electromyogram (EMG)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the transplanted facial segment
Description
This will be measured using nerve conduction studies (NCS)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the transplanted facial segment
Description
This will be measured using computerized tomography angiogram (CTA)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the transplanted facial segment
Description
This will be measured using magnetic resonance imaging (MRI)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the transplanted facial segment
Description
This will be measured using vision exams
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the upper extremity transplant
Description
This will be measured using pathology samples to check for rejection
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the upper extremity transplant
Description
This will be measured using electromyogram (EMG)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the upper extremity transplant
Description
This will be measured using nerve conduction studies (NCS)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the upper extremity transplant
Description
This will be measured using computerized tomography angiogram (CTA)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in function of the upper extremity transplant
Description
This will be measured using magnetic resonance imaging (MRI)
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in appearance of the transplanted facial segment
Description
This will be measured using photography
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5
Title
Change in appearance of the upper extremity transplant
Description
This will be measured using photography
Time Frame
Monthly for 6 months, every 6 months for 2 years, then annually up to year 5

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed and dated all required Institutional Review Board (IRB) approved consent forms. Male or female recipient between the ages of 18-64 years. Recipients do not need to be of the same sex as the donor. Facial composite tissue defect requiring facial transplantation as determined by the treating Plastic and Reconstructive Surgeon. Inclusive facial functional subunit tissue loss. Including but not limited to irreparable peri-oral, peri-orbital, and peri-nasal damage. Missing part of one or both hands and forearms. Must be HIV negative at the time of transplant. Crossmatch is negative at the time of transplant. Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in facial reconstruction. Patient has been encouraged to seek a second opinion from a Plastic Surgeon with specialized focus in upper extremity reconstruction. Willingness to participate in ongoing psychiatric, psychological and social work evaluations prior to and post-transplant surgery. The subject is able to complete pre-transplant examination and screening procedures. Patient has been approved by Patient Selection Committee for placement on the recipient waiting list. The subject is willing to continue immunosuppression regimen as directed by treating physician. Subject is willing and able to return to follow-up visits as described in treatment plan. Subjects must have autogenous tissue options available for reconstruction in event of graft failure. Normal glomerular filtration rate (GFR) >60. Negative pregnancy test within 48hrs of transplant for women of childbearing age and who agree to use a reliable form of contraception for one year following transplant. Exclusion Criteria: Uncontrolled infection or severe concomitant diseases which would exclude the recipient from transplantation Serious co-morbidities Positive serology for HIV; Hepatitis B Antigen Active malignancy within 5 years with the exclusion of non-melanoma Substance abuse disorders not currently under control (as determined by the Michigan Alcohol Screening Test - see Appendix N.1: Subjects with a score of 3 or more will be excluded) Body Dysmorphic disorder (see Appendix N.2 for screening tool). Less severe psychiatric conditions are addressed on a case by case basis Active Severe Psychiatric Illness Cognitive limitations affecting the patient's ability to provide informed consent Recent history of medical non-adherence Unstable social situation as evidence by lack of stable housing and/or lack of a supportive significant other. Recent history of medical non-adherence. Lack of stable housing and/or supportive significant other/caregiver throughout all phases of the study Currently active smoker within 1 year Subjects with any cognitive deficits related to a traumatic brain injury (TBI) and or any organic neurological disorders Any other psychological status that would hinder the success or safety of the transplantation. Level of amputation proximal to mid-humerus: some presence of proximal muscles is required to motor a functioning hand. Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post-transplant results History of amputation of less than six months: subject must be allowed to attempt prosthetic use prior to hand transplantation. This can be waived in cases where the recipient requires amputation/revision of the transplant site at the time of transplantation. However, if at all possible, it is highly encouraged that the patient has ruled out prosthetics as an alternative to transplantation. Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Calahan, BA
Phone
(929) 455-5826
Email
Thomas.Calahan@nyulangone.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eduardo Rodriguez, MD, DDS
Organizational Affiliation
NYU Langone Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10017
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elie Ramly, MD
Phone
929-455-5824
Email
Elie.Ramly@nyulangone.org
First Name & Middle Initial & Last Name & Degree
Thomas Calahan, BA
Phone
9294555826
Email
Thomas.Calahan@nyulangone.org
First Name & Middle Initial & Last Name & Degree
Eduardo Rodriguez, MD, DDS
First Name & Middle Initial & Last Name & Degree
Allyson Alfonso, BS
First Name & Middle Initial & Last Name & Degree
Jonathan Bass, MD
First Name & Middle Initial & Last Name & Degree
Aileen Blitz, MD
First Name & Middle Initial & Last Name & Degree
Arthur Kaplan, PhD
First Name & Middle Initial & Last Name & Degree
Daniel Ceradini, MD
First Name & Middle Initial & Last Name & Degree
David Chiu, MD
First Name & Middle Initial & Last Name & Degree
Mihye Choi, MD
First Name & Middle Initial & Last Name & Degree
Roberto Flores, MD
First Name & Middle Initial & Last Name & Degree
Bruce Gelb, MD
First Name & Middle Initial & Last Name & Degree
Alyssa Golas, MD
First Name & Middle Initial & Last Name & Degree
Jacques Hacquebord, MD
First Name & Middle Initial & Last Name & Degree
Jamie Levine, MD
First Name & Middle Initial & Last Name & Degree
Elie Ramly, MD
First Name & Middle Initial & Last Name & Degree
Allison Rojas, MS, RN
First Name & Middle Initial & Last Name & Degree
Stephen Ross, MD
First Name & Middle Initial & Last Name & Degree
Pierre Saadeh, MD
First Name & Middle Initial & Last Name & Degree
Sheel Sharma, MD
First Name & Middle Initial & Last Name & Degree
David Staffenberg, MD
First Name & Middle Initial & Last Name & Degree
Vishal Thanik, MD

12. IPD Sharing Statement

Learn more about this trial

Craniomaxillofacial and Upper Extremity Allotransplantation

We'll reach out to this number within 24 hrs